<DOC>
	<DOCNO>NCT00968630</DOCNO>
	<brief_summary>This phase II trial study immune response stem cell transplant human immunodeficiency virus ( HIV ) -positive patient hematologic cancer ( blood cancer ) . Studying sample blood HIV-positive patient cancer laboratory may help doctor learn change occur immune system stem cell transplant .</brief_summary>
	<brief_title>Immune Response After Stem Cell Transplant HIV-Positive Patients With Hematologic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Examine development donor-derived HIV-1-specific immune response follow hematopoietic cell transplant ( HCT ) treatment hematologic malignancy HIV+ patient . II . Examine affect HCT pool latently infect cluster differentiation ( CD ) 4+ T cell HIV+ patient give HCT treatment hematologic malignancy . OUTLINE : Patients undergo leukapheresis analysis HIV-1 latent reservoir baseline day +90 , +180 , +365 , +730 , annually thereafter feasible .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>HIV positive Treatment highly active antiretroviral therapy ( HAART ) least 1 month Viral load decrease &gt; = 1.5 log viral load &lt; 5000 copies/ml plasma HAART therapy Hematologic malignancy associate poor prognosis diagnosis hematopoietic cell therapy ( allogeneic autologous , include gene therapy ) indicate Approval allogenic regimen give Patient Care Conference DONOR : Autologous allogeneic gene modify cell allow A medical history noncompliance HAART medical therapy Inability provide inform consent DONOR : Allogeneic donor must HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>